Biogen Exec Says the Alzheimer's Drug Market "Will Develop Faster With Lilly in Play", but Can't Speculate What's Going to Happen With Donanemab's Label
渤健公司高管表示,在莉莉公司的參與下,阿爾茨海默病藥物市場“將更快地發展”,但不能猜測Donanemab的標籤會出現什麼情況。
Biogen Exec Says the Alzheimer's Drug Market "Will Develop Faster With Lilly in Play", but Can't Speculate What's Going to Happen With Donanemab's Label
渤健公司高管表示,在莉莉公司的參與下,阿爾茨海默病藥物市場“將更快地發展”,但不能猜測Donanemab的標籤會出現什麼情況。
譯文內容由第三人軟體翻譯。